The study is evaluating the combination of sofosbuvir plus velpatasvir (Epclusa). The combination was recently approved in the United States to treat all genotypes. The cure rates are up to and over 90%.
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic Hepatitis C Virus Infection
To read the entire clinical trial description, click here…
Share This Page